We are live on ! Find out more
TEVA icon

Teva Pharmaceutical Industries

537 hedge funds and large institutions have $16.3B invested in Teva Pharmaceutical Industries in 2018 Q2 according to their latest regulatory filings, with 83 funds opening new positions, 175 increasing their positions, 158 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more first-time investments, than exits

New positions opened: 83 | Existing positions closed: 48

60% more funds holding in top 10

Funds holding in top 10: 10 → 16 (+6)

11% more repeat investments, than reductions

Existing positions increased: 175 | Existing positions reduced: 158

6% more funds holding

Funds holding: 505 → 537 (+32)

0.35% less ownership

Funds ownership: 60.98% → 60.64% (-0.35%)

6% less capital inflows, than outflows

Capital inflows: $1.12B | Capital outflows: $1.19B

20% less call options, than puts

Call options by funds: $614M | Put options by funds: $765M

Holders
537
Holders Change
+32
Holders Change %
+6.34%
% of All Funds
12.24%
Holding in Top 10
16
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+60%
% of All Funds
0.36%
New
83
Increased
175
Reduced
158
Closed
48
Calls
$614​M
Puts
$765​M
Net Calls
-⁠$151​M
Net Calls Change
+$60.4​M

TEVA Hedge Fund Activity: Q2 2018 in Review

537 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceutical Industries (TEVA) for Q2 2018, worth a combined $16.3B — up 41% from $11.5B a quarter earlier.

Buyers outnumbered sellers: 83 funds opened new TEVA positions and 48 closed out — a net gain of 35 holders — while 175 added to existing stakes and 158 trimmed.

The largest buyer was PointState Capital, opening a new position worth an estimated $136M. The largest seller was JP Morgan Chase, cutting an estimated $330M.

  • 537 institutional investors held Teva Pharmaceutical Industries (TEVA) as of Q2 2018, up from 505 in Q1 2018.
  • Funds reported $16.3B of Teva Pharmaceutical Industries stock for Q2 2018, up 41% quarter-over-quarter.
  • 83 funds opened new Teva Pharmaceutical Industries positions in Q2 2018 and 48 closed out, a net change of +35 holders.
  • The largest Teva Pharmaceutical Industries buyer in Q2 2018 was PointState Capital, an estimated $136M added.
  • The largest Teva Pharmaceutical Industries seller in Q2 2018 was JP Morgan Chase, an estimated $330M sold.

Based on aggregated 13F filings for Q2 2018.